Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)
NCTID
NCT06345898
(View at clinicaltrials.gov)
Description
This trial is to evaluate the safety and efficacy of JWK002 treatment of X-linked retinoschisis(XLRS). This study will enroll subjects aged 5-18 years old to receive a sub-retinal injection of JWK002.
(Show More)
Development Status
Active
Indication
X-Linked Retinoschisis
Disease Ontology Term
DOID:0060763
Compound Name
JWK002
Sponsor
West China Hospital
Funder Type
Other
Recruitment Status
Recruiting
Enrollment Count
12
Results Posted
Not Available
Therapy Information
Target Gene/Variant
RS1
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Functional gene replacement
Route of Administration
Subretinal
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
AAV8
Editor Type
none
Dose 1
Undisclosed low dose
Dose 2
Undisclosed medium dose
Dose 3
Undisclosed high dose
Dose 4
Dose 5
Study Record Dates
Current Stage
Early phase1
Submit Date
2024-03-28
Completion Date
2033-11-30
Last Update
2025-02-07
Participation Criteria
Eligible Age
5 Years - 18 Years
Standard Ages
Child, Adult
Sexes Eligible for Study
MALE
Locations
No.of Trial Sites
1
Locations
China
Regulatory Information
Has US IND
False
FDA Designations
Recent Updates
Investigator-initiated trial conducted at West China Hospital
Resources/Links
Resources/Links
No External Links Available.